Feasibility study of biweekly CPT-11 plus CDDP for S-1- and paclitaxel-refractory, metastatic gastric cancer

Anticancer Research

Volumn 26, Issue 2 B, 2006, Pages 1595-1598

  Yoshida, Tatsuya ^a   Yoshikawa, Takaki ^a   Tsuburaya, Akira ^a   Kobayashi, Osamu ^a   Hasegawa, Shinichi ^a   Osaragi, Tomohiko ^a   Sairenji, Motonori ^a  

^a KANAGAWA CANCER CENTER   (Japan)

Author keywords

Cisplatin; CPT 11; Metastatic gastric cancer; Paclitaxel refractory; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CISPLATIN; IRINOTECAN; PACLITAXEL;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; BONE MARROW; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; ENZYME BLOOD LEVEL; FATIGUE; FEASIBILITY STUDY; FEMALE; HEART PALPITATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOTENSION; KIDNEY FUNCTION; LEUKOPENIA; LIVER FUNCTION; MALE; METASTASIS; NAUSEA; NEUTROPENIA; PANCYTOPENIA; PIGMENT DISORDER; PRIORITY JOURNAL; SENSORY NEUROPATHY; SIDE EFFECT; STOMACH ADENOCARCINOMA; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RESPONSE; TUMOR RECURRENCE; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; OXONIC ACID; PACLITAXEL; PYRIDINES; STOMACH NEOPLASMS; TEGAFUR;

EID: 33645821090     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Pyrhonen S, Kuitunen T, Nyandoto P et al: Randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71: 587-591, 1995.
2. Murad AM, Santiago FF, Petroianu A et al: Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72: 37-41, 1993.
3. Glimelius B, Hoffman K, Haglund U et al: Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 5: 189-190, 1994.
4. Wils JA, Klein HO, Wagener DJ et al: Sequential high-dose methotrexate and fluorouracil combined with doxorubicin - a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 9: 827-831, 1991.
5. Kelsen D, Atiq OT, Saltz L et al: FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 10: 541-548, 1992.
6. Kim NK, Park YS, Heo DS et al: A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 71: 3813-3818, 1993.
7. Wilke H, Wils J, Rougier P et al: Preliminary analysis of a randomized phase III trial of FAMTX versus ELF versus cisplatin/FU in advanced gastric cancer (GC). A trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group and the AIO (Arbeitsgemeinschaft Internistische Onkologie). Proc Am Soc Clin Oncol 14: 206, 1995.
8. Webb A, Cunningham D, Scarffe JH et al: Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15: 261-267, 1997.
9. Koizumi W, Kurihara M, Nakano S et al: Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 58: 191-197, 2000.
10. Sakata Y, Ohtsu A, Horikoshi N et al: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur-0.4M gimestat-1M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34: 1715-1720, 1998.
11. Yamada Y, Shirao K, Ohtsu A et al: Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity. Ann Oncol 12: 1133-1137, 2001.
12. Yamaguchi K, Tada M, Horikoshi N et al: Phase II study of paclitaxel 3-h infusion in patients with advanced gastric cancer. Gastric Cancer 5: 55-57, 2002.
13. Taguchi T, Sakata Y, Kanamaru R et al: Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer. A Japanese Cooperative Study Group trial (group A). Jpn J Cancer Chemother 25: 1915-1924, 1998.
14. Mai M, Sakata Y, Kanamaru R et al: A late phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer. A Japanese Cooperative Study Group Trial (group B). Jpn J Cancer Chemother 26: 487-496, 1999.
15. Futatsuki K, Wakui A, Nakao I et al: Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. Jpn J Cancer Chemother 21: 1033-1038, 1994.
16. Boku N, Ohtsu A, Shimada Y et al: Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 17: 319-323, 1999.
17. Ajani JA, Baker J, Pisters PW et al: CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer 94: 641-646, 2002.
18. Koizumi W, Kurihara M, Satoh A et al: Phase I/II study of bi-weekly irinotecan plus cisplatin in the treatment of advanced gastric cancer. Anticancer Res 25: 1257-1262, 2005.
19. Ohtsu A, Shimada Y, Shirao K et al: Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 21: 54-59, 2003.
20. Cho H, Tsuburaya A, Kobayashi O et al: Dose dense paclitaxel as second-line treatment for S-1 or UFT refractory gastric cancer. Proc Am Soc Clin Oncol 22: 357, 2003.
21. Anton A, Aranda E, Carrato A et al: Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study. Methods Find Exp Clin Pharmacol 25: 639-643, 2003.
22. Yoshimatsu K, Kato H, Ishibashi K et al: Second-line chemotherapy with low-dose CPT-11 and cisplatin for colorectal cancer resistant to 5-FU-based chemotherapy. Cancer Chemother Pharmacol 52: 465-468, 2003.
23. Shimada S, Yagi Y, Kuramoto M et al: Second-line chemotherapy with combined irinotecan and low-dose cisplatin for patients with metastatic gastric carcinoma resistant to 5-fluorouracil. Oncol Rep 10: 687-691, 2003.
24. Swisher EM, Mutch DG, Rader JS et al: Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecol Oncol 66: 480-486, 1997.
25. Gore M, ten Bokkel Huinink W, Carmichael J et al: Clinical evidence for topotecan-paclitaxel non-cross-resistance in ovarian cancer. J Clin Oncol 19: 1893-1900, 2001.